The randomized controlled trial of the THP-COP therapy versus CHOP therapy for T-cell lymphoma with or without P-glycoprotein expressio
Phase 2
Recruiting
- Conditions
- T cell Lymphoma
- Registration Number
- JPRN-UMIN000004092
- Lead Sponsor
- Osaka Lymphoma Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 94
Inclusion Criteria
Not provided
Exclusion Criteria
1)Previously treated patients 2)Other active multiple cancers 3)Severe complications (liver, kidney, cardiac disease, infection, etc) 4)Severe cardiac disfunction 5)History of angina pectoris, myocardial infarction 6)pregnant women and women suspected to be pregnant 7)HBV carrier (hepatitis B surface antigen positivity, HBc antibody positive or HBs antibody positivity), HCV positivity 8)HTLV-1 positivity 9)HIV positivity 10)History of severe drug hypersensitivity 11)judged to be inappropriate for other reasons by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Remission rate (Complete remission, partial remission)
- Secondary Outcome Measures
Name Time Method The 1-, 3-, 5-year overall survival 50% survival rate The 1-, 3-, 5-year disease free survival